Neovasc Inc. NVCN

Healthcare Medical Instruments & Supplies

Neovasc Inc is a specialty medical device company. It develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products the Neovasc Reducer (Reducer), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara, for the transcatheter treatment of mitral valve disease, which is under clinical investigation in the United States, Canada, Israel and Europe. The company earns revenue from one source, the Reducer.

NDAQ:NVCN - Post by User

Neovasc Inc. > Leerink downgraded from $5 to $2 on March 28th

<< Previous

Bullboard Posts

Next >>

Comment by pleazu69on Apr 19, 2018 4:45am

86 Views

Post# 27909161

RE:Leerink downgraded from $5 to $2 on March 28th

$2 wow that would make allot of dreams come true
even if they downgraded to $1 thats over 1500% profit from todays prices
and that target was before the warrant money hit the bank :)

rimbus wrote: https://thefly.com/landingPageNews.php?id=2706122&headline=NVCN-Neovasc-price-target-lowered-to--from--at-Leerink

Neovasc price target lowered to $2 from $5 at Leerink Leerink analyst Danielle Antalffy lowered her price target for Neovasc to $2 from $5 to reflect significant dilution. The analyst believes the solvency risk is largely mitigated following Q4 sales of $1.2M and as Tiara clinical trials continue to progress. Antalffy reiterates an Outperform rating on the shares.